Biomarkers of endocrine therapy-resistance in breast cancers;Marqueurs biologiques de résistance à l'hormonothé rapie dans les cancers du sein

Bulletin du Cancer

Volumn 97, Issue 8, 2010, Pages 951-963

  De Cremoux, P ^a   Debled, M ^b   Bonnefoi, H ^b   Cottu, P ^a  

^a INSTITUT CURIE   (France)

^b Institute Bergonie   (France)

Author keywords

Breast cancer; ER; HER2; Hormone receptor; Molecular signature; PR; Proliferation

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; PROGESTERONE RECEPTOR; SIGNAL PEPTIDE; TUMOR MARKER;

BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; NEOPLASMS, HORMONE-DEPENDENT; PHARMACOGENETICS; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PHARMACOGENETICS; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; RECEPTORS, GROWTH FACTOR; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77956543888     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2010.1137     Document Type: Review

References (119)

1. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008 ; 9 : 45-53.
2. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007 ; 25 : 486-92.
3. Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5-year of tamoxifen. J Clin Oncol 2008 ; 26 : 1948-55.
4. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2-3-years' tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 2007 ; 369 : 559-70.
5. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, et al. Comparison of HER2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008 ; 13 : 838-44.
6. Lower EE, Glass EL, Bradley DA, Blau R, Heffelfinger S. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005 ; 90 : 65-70.
7. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res 2009 ; 69 : 4951-3.
8. Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 2008 ; 5 : 206-19.
9. Panel ATME. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996 ; 14 : 2843-77.
10. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999 ; 17 : 1474-81.
11. de Cremoux P, Tran-Perennou C, Elie C, Boudou E, Barbaroux C, Poupon MF, et al. Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays. Biochem Pharmacol 2002 ; 64 : 507-15.
12. Group EBCtc. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 ; 365 : 1687-717.
13. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007 ; 25 : 4772-8.
14. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003 ; 21 : 1973-9.
15. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007 ; 25 : 5287-312.
16. Allred DC, Mohsin SK. ER expression is not bimodal in breast cancer. Am J Clin Pathol 2005 ; 124 : 474-5 (author reply 475-6).
17. Bezwoda WR, Esser JD, Dansey R, Kessel I, Lange M. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 1991 ; 68 : 867-72.
18. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992 ; 10 : 1284-91.
19. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000 ; 89 : 111-7.
20. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003 ; 17 : 575-88.
21. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005 ; 23 : 7721-35.
22. Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009 ; 114 : 287-99.
23. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982 ; 10 : 7895-903.
24. Mathelin C, Tomasetto C, Rio MC. Trefoil factor 1 (pS2/TFF1), a peptide with numerous functions. Bull Cancer 2005 ; 92 : 773-81.
25. Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, Lin J, et al. Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology 2009 ; 150 : 4473-83.
26. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003 ; 144 : 4562-74.
27. Ochsner SA, Steffen DL, Hilsenbeck SG, Chen ES, Watkins C, McKenna NJ. GEMS (gene expression metasignatures), a web resource for querying meta-analysis of expression microarray datasets: 17-beta-estradiol in MCF-7 cells. Cancer Res 2009 ; 69 : 23-6.
28. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996 ; 93 : 5925-30.
29. Balfe P, McCann A, McGoldrick A, McAllister K, Kennedy M, Dervan P, et al. Estrogen receptor alpha and beta profiling in human breast cancer. Eur J Surg Oncol 2004 ; 30 : 469-74.
30. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008 ; 26 : 3727-34.
31. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998 ; 247 : 75-8.
32. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res 1998 ; 26 : 3505-12.
33. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JA. Update on estrogen signaling. FEBS Lett 2003 ; 546 : 17-24.
34. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR, Hanby AM. Estrogen receptor beta: what it means for patients with breast cancer ? Lancet Oncol 2004 ; 5 : 174-81.
35. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004 ; 10 : 5769-76.
36. Vinayagam R, Sibson DR, Holcombe C, Aachi V, Davies MP. Association of estrogen receptor beta-2 (ER beta-2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer-a retrospective study. BMC Cancer 2007 ; 7 : 131.
37. de Cremoux P, Bieche I, Tran-Perennou C, Vignaud S, Boudou E, Asselain B, et al. Interlaboratory quality control for hormone-dependent gene expression in human breast tumors using real time reverse transcription-polymerase chain reaction. Endocr Relat Cancer 2004 ; 11 : 489-95.
38. Davies MP, O'Neill PA, Innes H, Sibson DR, Prime W, Holcombe C, et al. Correlation of mRNA for estrogen receptor beta splice variants ERbeta1, ERbeta-2/ERbetacx and ERbeta-5 with outcome in endocrine-treated breast cancer. J Mol Endocrinol 2004 ; 33 : 773-82.
39. Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stal O, Linn S, et al. Estrogen receptor: a phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst 2009 ; 101 : 1725-9.
40. Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res 2000 ; 60 : 4026-9.
41. Barone I, Cui Y, Herynk MH, Corona-Rodriguez A, Giordano C, Selever J, et al. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 2009 ; 69 : 4724-32.
42. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009 ; 9 : 631-43.
43. Eccles D, Gerty S, Simmonds P, Hammond V, Ennis S, Altman DG. Prospective study of outcomes in sporadic versus hereditary breast cancer (POSH): study protocol. BMC Cancer 2007 ; 7 : 160.
44. Tapper W, Hammond V, Gerty S, Ennis S, Simmonds P, Collins A, et al. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res 2008 ; 10 : R108.
45. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 2005 ; 336 : 1023-7.
46. Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, et al. Expression of ERalpha36, a novel variant of estrogen receptor alpha, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 2009 ; 27 : 3423-9.
47. Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol 2005 ; 19 : 2671-84.
48. Le Romancer M, Treilleux I, Leconte N, Robin-Lespinasse Y, Sentis S, Bouchekioua-Bouzaghou K, et al. Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell 2008 ; 31 : 212-21.
49. Musgrove EA, Sergio CM, Anderson LR, Inman CK, McNeil CM, Alles MC, et al. Identification of downstream targets of estrogen and c-Myc in breast cancer cells. Adv Exp Med Biol 2008 ; 617 : 445-51.
50. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and estrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005 ; 12 (Suppl 1) : S47-59.
51. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. Regulation of ERBB2 by estrogen receptor-PAX2 determines response to tamoxifen. Nature 2008 ; 456 : 663-6.
52. Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT. The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat 2009 ; 116 : 225-37.
53. Alkner S, Bendahl PO, Grabau D, Lovgren K, Stal O, Ryden L, et al. AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann Oncol 2010 ; 21 : 238-44.
54. Lopez-Tarruella S, Schiff R. The dynamics of estrogen receptor status in breast cancer: reshaping the paradigm. Clin Cancer Res 2007 ; 13 : 6921-5.
55. Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 2007 ; 13 : 7029-36.
56. Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009 ; 69 : 1416-28.
57. Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res treat 2007 ; 105 (Suppl 1) : 33-43.
58. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008 ; 100 : 1380-8.
59. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER2/neu proto-oncogen in human breast and ovarian cancer. Science 1989 ; 244 : 707-12.
60. Hudis CA. Trastuzumab :mechanism of action and use in clinical practice. N Engl J Med 2007 ; 357 : 39-51.
61. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005 ; 11 : 4741-8.
62. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003 ; 95 : 353-61.
63. Lal P, Tan LK, Chen B. Correlation of HER2 status with estrogen and progesterone receptors and histologic features in 3.655 invasive breast carcinomas. Am J Clin Pathol 2005 ; 123 : 541-6.
64. Dowsett M. Overexpression of HER2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001 ; 8 : 191-5.
65. Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990 ; 5 : 1001-6.
66. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992 ; 24 : 85-95.
67. Balasenthil S, Barnes CJ, Rayala SK, Kumar R. Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett 2004 ; 567 : 243-7.
68. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995 ; 270 : 1491-4.
69. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001 ; 276 : 9817-24.
70. de Cremoux P, Rosenberg D, Goussard J, Bremont-Weil C, Tissier F, Tran-Perennou C, et al. Expression of progesterone and estradiol receptors in normal adrenal cortex, adrenocortical tumors, and primary pigmented nodular adrenocortical disease. Endocr Relat Cancer 2008 ; 15 : 465-74.
71. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009 ; 69 : 3955-62.
72. Heck S, Rom J, Thewes V, Becker N, Blume B, Sinn HP, et al. Estrogen-related receptor alpha expression and function is associated with the transcriptional coregulator AIB1 in breast carcinoma. Cancer Res 2009 ; 69 : 5186-93.
73. Deblois G, Hall JA, Perry MC, Laganiere J, Ghahremani M, Park M, et al. Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity. Cancer Res 2009 ; 69 : 6149-57.
74. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008 ; 283 : 31079-86.
75. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol 2009 ; 950201.
76. Green MD, Francis PA, Gebski V, Harvey V, Karapetis C, Chan A, et al. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann Oncol 2009 ; 20 : 1813-7.
77. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007 ; 25 : 3816-22.
78. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009 ; 27 : 5529-37.
79. Johnston S, Pippen Jr J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009 ; 27 : 5538-46.
80. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009 ; 27 : 2630-7.
81. Remvikos Y, Mosseri V, Asselain B, Fourquet A, Durand JC, Pouillart P, et al. S-phase fractions of breast cancer predict overall and postrelapse survival. Eur J Cancer 1997 ; 33 : 581-6.
82. Chang J, Ormerod M, Powles TJ, Allred DC, Ashley SE, Dowsett M, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000 ; 89 : 2145-52.
83. Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 2003 ; 89 : 1035-41.
84. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008 ; 100 : 207-12.
85. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008 ; 26 : 5569-75.
86. Dowsett M. Introduction to sessions on "predicting personal risk for breast cancer". Breast Cancer Res 2008 ; 10 (Suppl 4) : S9.
87. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007 ; 99 : 167-70.
88. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005 ; 92 : 147-55.
89. Anderson H, Bulun S, Smith I, Dowsett M. Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 2007 ; 106 : 49-54.
90. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008 ; 10 : R65.
91. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumors. Nature 2000 ; 406 : 747-52.
92. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001 ; 98 : 10869-74.
93. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003 ; 100 : 8418-23.
94. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003 ; 100 : 10393-8.
95. Lyng MB, Laenkholm AV, Vach W, Pallisgaard N, Knoop A, Ditzel HJ. Predictive gene expression profile in breast cancer patients treated by tamoxifen. Breast Cancer Res Treat 2007 ; 106 (Supplement 1) : 167.
96. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 ; 351 : 2817-26.
97. Sparano JA, Paik S. Development of the 21 gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008 ; 26 : 721-8.
98. Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006 ; 8 : R25.
99. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005 ; 11 : 3315-9.
100. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006 ; 7 : 347-50.
101. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 2008 ; 14 : 1744-52.
102. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004 ; 5 : 607-16.
103. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009 ; 360 : 790-800.
104. Jordan VC, Collins MM, Rowsby L, Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 1977 ; 75 : 305-16.
105. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003 ; 95 : 1758-64.
106. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006 ; 80 : 61-74.
107. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007 ; 116 : 496-526.
108. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005 ; 23 : 9312-8.
109. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007 ; 101 : 113-21.
110. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007 ; 25 : 5187-93.
111. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007 ; 25 : 3837-45.
112. Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 2007 ; 96 : 2224-31.
113. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005 ; 91 : 249-58.
114. Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005 ; 7 : R284-R290.
115. Cuzick J, Sestak I, Cella D, Fallowfield L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008 ; 9 : 1143-8.
116. Wang L, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010 ; 70 : 319-28.
117. Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, et al. A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 2008 ; 14 : 811-6.
118. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007 ; 9 : R37.
119. Moore TW, Mayne CG, Katzellenbogen JA. Not Picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol 2010 ; 24 : 683-95 (Epub ahead of print).